Aurinia Pharmaceuticals (AUPH) Common Equity (2017 - 2026)

Aurinia Pharmaceuticals has reported Common Equity for 10 years, with the latest figure at $567.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 62.09% year-over-year to $567.6 million; the trailing twelve-month figure through Mar 2026 stood at $567.6 million (up 62.09% YoY), and the FY2025 full-year result was $581.3 million, up 54.0% from the prior year.
• Common Equity for Q1 2026 stood at $567.6 million, down from $581.3 million in the prior quarter.
• The five-year high for Common Equity was $581.3 million in Q4 2025, with the low at $335.3 million in Q2 2025.
• Historically, Common Equity has averaged $408.4 million across 5 years, with a median of $390.4 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity slipped 15.37% — and 2026, when it surged 62.09%.
• Aurinia Pharmaceuticals' Common Equity stood at $405.4 million in 2022, then fell by 6.78% to $378.0 million in 2023, then declined by 0.13% to $377.5 million in 2024, then soared by 54.0% to $581.3 million in 2025, then slipped by 2.36% to $567.6 million in 2026.
• The last three Common Equity figures came in at $567.6 million (Q1 2026), $581.3 million (Q4 2025), and $365.8 million (Q3 2025), per Business Quant data.